Therapy of meningeal melanocytomas

BRAF V600E mutation in two distinct meningeal melanocytomas associated with a nevus of Ota.

Introduction Meningeal melanocytomas are rare tumors of the CNS that develop from melanocytes that are present in leptomeninges, with differing pigmented appearance. They generally occur in the posterior fossa and the spinal cord. This lesion may manifest at any age, but most patients are in the fifth decade of life. Occasionally, these tumors appear in a complex neurocutaneous grouping with ot...

Combination intrathecal therapy for meningeal leukemia: two versus three drugs.

The comparative effectiveness of intrathecal (IT) combination chemotherapy using two agents, methotrexate (MTX) and hydrocortisone (HDC), and three agents, MTX, HDC, and cytosine arabinoside (CA), in treating meningeal leukemia was determined in a randomized Southwest Oncology Group study. Following central nervous system (CNS) remission induction the same regimen was used for periodic maintena...

Treatment of Meningeal Malignancy.

Meningeal metastasis from cancer has become an increasingly frequent problem as the treatment of systemic disease improves. Leukemia, lymphoma and solid tumors may all metastasize to the meninges, where the blood-brain barrier may provide a sanctuary from cytotoxic concentrations of chemotherapeutic agents. Because meningeal disease may be clinically silent or may present with unusual signs and...

Intracranial melanocytomas and melanosis oculi: case report and literature review

Malignant primary meningeal tumors.

1) Out of 160 primary meningeal tumors surgically treated, 10 cases had histologically malignant tumors. Of them two cases of sarcoma and one case of meningioma with marked invasiveness were filed in malignant (sarcoma) group, and six cases of angioblastic meningioma of hemangiopericytoma type and one case of meningioma with partial invasiveness in semi malignant group. 2) Average duration of s...